Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ANGO Stock Forecast 2025-2026
$9.60
Current Price
$391.45M
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ANGO Price Targets
+66.7%
To High Target of $16.00
+66.7%
To Median Target of $16.00
+56.3%
To Low Target of $15.00
ANGO Price Momentum
+3.8%
1 Week Change
+1.1%
1 Month Change
+65.2%
1 Year Change
+4.8%
Year-to-Date Change
-28.9%
From 52W High of $13.50
+75.5%
From 52W Low of $5.47
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching AngioDynamics (ANGO) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ANGO and similar high-potential opportunities.
Latest ANGO Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, ANGO has a bullish consensus with a median price target of $16.00 (ranging from $15.00 to $16.00). Currently trading at $9.60, the median forecast implies a 66.7% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Yi Chen at HC Wainwright & Co., projecting a 66.7% upside. Conversely, the most conservative target is provided by Yi Chen at HC Wainwright & Co., suggesting a 56.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ANGO Analyst Ratings
3
Buy
0
Hold
0
Sell
ANGO Price Target Range
Low
$15.00
Average
$16.00
High
$16.00
Current: $9.60
Latest ANGO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ANGO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 7, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $16.00 |
| Jan 10, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $15.00 |
| Dec 10, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $14.00 |
| Oct 4, 2024 | Canaccord Genuity | William Plovanic | Buy | Maintains | $12.00 |
| Oct 4, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $14.00 |
| Sep 20, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $14.00 |
| Jul 17, 2024 | Canaccord Genuity | William Plovanic | Buy | Maintains | $13.00 |
| Jul 17, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $14.00 |
| May 22, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $14.00 |
| Apr 5, 2024 | Oppenheimer | Steven Lichtman | Outperform | Upgrade | $12.00 |
| Jan 9, 2024 | Raymond James | Jayson Bedford | Outperform | Maintains | $10.00 |
| Jan 8, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $18.00 |
| Oct 6, 2023 | Raymond James | Jayson Bedford | Outperform | Maintains | $12.00 |
| Oct 5, 2023 | Canaccord Genuity | William Plovanic | Buy | Maintains | $17.00 |
| Oct 5, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $20.00 |
| Sep 25, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Initiates | $19.00 |
| Jul 13, 2023 | Canaccord Genuity | William Plovanic | Buy | Maintains | $20.00 |
| Apr 17, 2023 | Raymond James | Jayson Bedford | Outperform | Downgrade | $13.00 |
| Apr 3, 2023 | Raymond James | Jayson Bedford | Strong Buy | Maintains | $14.00 |
| Jan 6, 2023 | Raymond James | Jayson Bedford | Strong Buy | Maintains | $22.00 |
Angiodynamics Inc. (ANGO) Competitors
The following stocks are similar to AngioDynamics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ANGO
AngioDynamics
mkt cap
391.45M
Angiodynamics Inc. (ANGO) Financial Data
Angiodynamics Inc. has a market capitalization of $391.45M with a P/E ratio of 41.4x. The company generates $283.32M in trailing twelve-month revenue with a -14.6% profit margin.
Revenue growth is -4.2% quarter-over-quarter, while maintaining an operating margin of -9.2% and return on equity of -20.5%.
Valuation Metrics
Market Cap
$391.45M
Enterprise Value
$355.76M
P/E Ratio
41.4x
PEG Ratio
-40.0x
Price/Sales
1.4x
Growth & Margins
Revenue Growth (YoY)
-4.2%
Gross Margin
+54.0%
Operating Margin
-9.2%
Net Margin
-14.6%
EPS Growth
-4.2%
Financial Health
Cash/Price Ratio
+11.5%
Current Ratio
2.2x
Debt/Equity
5.8x
ROE
-20.5%
ROA
-6.6%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Angiodynamics Inc. (ANGO) Business Model
About Angiodynamics Inc.
What They Do
Develops minimally invasive medical devices.
Business Model
The company generates revenue through the development, manufacture, and sale of innovative medical devices used in various healthcare settings. Their product offerings include devices for oncology, vascular interventions, and peripheral diseases, which are designed to improve patient outcomes and operational efficiency in medical procedures.
Additional Information
Angiodynamics is committed to research and development to enhance its product offerings, including radiofrequency ablation devices and angiographic catheters. The company actively seeks to expand its market presence through strategic initiatives and collaborations, adapting to the changing needs of the healthcare industry.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
748
CEO
Mr. James C. Clemmer
Country
United States
IPO Year
2004
Website
www.angiodynamics.comAngiodynamics Inc. (ANGO) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
CHE Stock Falls Despite Q1 Earnings & Revenue Beat, Gross Margin Declines
Chemed delivers first-quarter top-line growth across two of its segments, VITAS and Roto-Rooter.
Apr 25, 2025
By Zacks Equity Research
Analyst Blog
Penumbra Q1 Earnings & Revenues Top Estimates, Stock Up, Margins Expand
PEN reports better-than-expected earnings and revenues in the first quarter of 2025.
Apr 24, 2025
By Zacks Equity Research
Analyst Blog
Thermo Fisher's Q1 Earnings Top Estimates, Revenues Beat, Stock Up
TMO continues to advance its growth strategy and trusted partner status with customers in the first quarter of 2025.
Apr 23, 2025
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
AngioDynamics (ANGO) and Anixa Biosciences Inc (ANIX) have shown performance metrics relative to their sector in 2023, indicating their market positioning.
Why It Matters
Performance comparisons indicate how well AngioDynamics and Anixa Biosciences are managing market conditions versus their sector, influencing investor sentiment and potential investment decisions.
Source: Zacks Investment Research
Market Sentiment:
Positive
Wall Street Analysts Think AngioDynamics (ANGO) Could Surge 68.28%: Read This Before Placing a Bet
21 days ago
Quick Summary
Wall Street analysts' price targets suggest a potential upside of 68.3% for AngioDynamics (ANGO), supported by positive earnings estimate revisions.
Why It Matters
AngioDynamics (ANGO) shows a potential 68.3% upside per analyst targets, with positive earnings revisions suggesting growth, impacting investor sentiment and stock valuation.
Source: Zacks Investment Research
Market Sentiment:
Positive
Medical Device Maker AngioDynamics Stock Jumps On Better Than Expected Q3 Earnings, Upbeat Annual Guidance
26 days ago
Quick Summary
AngioDynamics Inc. (NASDAQ: ANGO) reported Q3 2025 adjusted EPS of 3 cents, surpassing the consensus estimate of a 13-cent loss.
Why It Matters
AngioDynamics' better-than-expected EPS indicates strong operational performance, potentially boosting investor confidence and positively impacting stock price.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
AngioDynamics, Inc. (NASDAQ: ANGO) will hold its Q3 2025 earnings conference call on April 2, 2025, at 8:00 AM ET, featuring executives and analysts from various firms.
Why It Matters
The earnings call provides key insights into AngioDynamics' financial performance and strategic direction, influencing stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
AngioDynamics, Inc. reported its Q3 fiscal 2025 results, ending February 28, showing year-over-year growth in pro forma net sales. Further details on financial performance were not provided.
Why It Matters
AngioDynamics' Q3 financial results indicate growth in sales, reflecting its market position and potential for future profitability, influencing investor confidence and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
AngioDynamics (ANGO) reported Q2 earnings of $0.03 per share, surpassing the Zacks Consensus Estimate of a loss of $0.13. This is an improvement from a loss of $0.16 per share a year earlier.
Why It Matters
AngioDynamics' earnings beat expectations, signaling improved financial health and potential growth, which can positively influence investor sentiment and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About ANGO Stock
What is Angiodynamics Inc.'s (ANGO) stock forecast for 2025?
Based on our analysis of 7 Wall Street analysts, Angiodynamics Inc. (ANGO) has a median price target of $16.00. The highest price target is $16.00 and the lowest is $15.00.
Is ANGO stock a good investment in 2025?
According to current analyst ratings, ANGO has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $9.60. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ANGO stock?
Wall Street analysts predict ANGO stock could reach $16.00 in the next 12 months. This represents a 66.7% increase from the current price of $9.60. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Angiodynamics Inc.'s business model?
The company generates revenue through the development, manufacture, and sale of innovative medical devices used in various healthcare settings. Their product offerings include devices for oncology, vascular interventions, and peripheral diseases, which are designed to improve patient outcomes and operational efficiency in medical procedures.
What is the highest forecasted price for ANGO Angiodynamics Inc.?
The highest price target for ANGO is $16.00 from Yi Chen at HC Wainwright & Co., which represents a 66.7% increase from the current price of $9.60.
What is the lowest forecasted price for ANGO Angiodynamics Inc.?
The lowest price target for ANGO is $15.00 from Yi Chen at HC Wainwright & Co., which represents a 56.3% increase from the current price of $9.60.
What is the overall ANGO consensus from analysts for Angiodynamics Inc.?
The overall analyst consensus for ANGO is bullish. Out of 7 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $16.00.
How accurate are ANGO stock price projections?
Stock price projections, including those for Angiodynamics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 28, 2025 10:04 AM UTC